Revenue $24.40B, up 38.6% on a year earlier. U.S. Revenue $15.14B, up 33.9%. Mounjaro Revenue $10.72B, up 64.6%. Diluted EPS $7.22 against $6.21.
| Q3 FY26 | Q2 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $24.40B | $22.97B | $17.60B | +38.6% |
| Net income | $6.45B | $7.09B | $5.58B | +15.6% |
| Diluted EPS | $7.22 | $7.94 | $6.21 | |
| Operating cash flow | $11.40B | $10.69B | $8.84B | +29.0% |
| Capital expenditures | -$3.18B | -$2.93B | -$2.09B | |
| Free cash flow | $8.22B | $7.76B | $6.75B | +21.8% |
| Q3 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|
| U.S. Revenue | $15.14B | $11.30B | +33.9% |
| Mounjaro Revenue | $10.72B | $6.52B | +64.6% |
| Zepbound Revenue | $5.35B | $3.59B | +49.2% |
| Verzenio Revenue | $1.51B | $1.47B | +2.8% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “ELI LILLY (LLY) Q3 FY26 earnings: results and KPIs”, stockatlas.com/companies/LLY/earnings/2026-q3/, data as of 3 November 2026. Links to this page are welcome.
